Compare Stocks: CAPR, ADMA, VCEL, and AGIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$8.95 +0.6%	$9.21	$7.21 ▼ $20.46	$1.99B	0.78	1.95 million shs	2.13 million shs
AGIO Agios Pharmaceuticals	$33.61 +2.0%	$34.57	$22.24 ▼ $46.00	$1.97B	0.6	755,708 shs	956,673 shs
CAPR Capricor Therapeutics	$9.42 +10.0%	$9.97	$2.96 ▼ $40.37	$497.67M	0.72	6.20 million shs	3.94 million shs
VCEL Vericel	$40.03 -0.4%	$43.45	$28.95 ▼ $49.32	$2.06B	1.04	476,183 shs	536,419 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.37%	-5.82%	-4.71%	+7.10%	-43.28%
AGIO Agios Pharmaceuticals	+0.43%	-4.85%	-2.02%	-3.54%	-10.27%
CAPR Capricor Therapeutics	0.00%	-0.93%	+14.90%	-69.84%	+37.62%
VCEL Vericel	+1.23%	+3.13%	-7.75%	+0.27%	+21.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$8.95 +0.6%	$9.21	$7.21 ▼ $20.46	$1.99B	0.78	1.95 million shs	2.13 million shs
AGIO Agios Pharmaceuticals	$33.61 +2.0%	$34.57	$22.24 ▼ $46.00	$1.97B	0.6	755,708 shs	956,673 shs
CAPR Capricor Therapeutics	$9.42 +10.0%	$9.97	$2.96 ▼ $40.37	$497.67M	0.72	6.20 million shs	3.94 million shs
VCEL Vericel	$40.03 -0.4%	$43.45	$28.95 ▼ $49.32	$2.06B	1.04	476,183 shs	536,419 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.37%	-5.82%	-4.71%	+7.10%	-43.28%
AGIO Agios Pharmaceuticals	+0.43%	-4.85%	-2.02%	-3.54%	-10.27%
CAPR Capricor Therapeutics	0.00%	-0.93%	+14.90%	-69.84%	+37.62%
VCEL Vericel	+1.23%	+3.13%	-7.75%	+0.27%	+21.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	108.57% Upside
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.25	22.73% Upside
CAPR Capricor Therapeutics	2.33	Hold	$30.25	221.13% Upside
VCEL Vericel	2.67	Moderate Buy	$58.40	45.89% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ADMA, VCEL, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/14/2026	CAPR Capricor Therapeutics	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/24/2026	AGIO Agios Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	3.93	$0.66 per share	13.61	$2.01 per share	4.45
AGIO Agios Pharmaceuticals	$54.03M	37.14	N/A	N/A	$20.46 per share	1.64
CAPR Capricor Therapeutics	$22.27M	24.59	N/A	N/A	$5.53 per share	1.70
VCEL Vericel	$276.26M	7.42	$0.55 per share	72.39	$7.01 per share	5.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	12.79	10.53	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	85.17	47.65	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)

Latest CAPR, ADMA, VCEL, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
CAPR Capricor Therapeutics	N/A	7.35	7.35
VCEL Vericel	N/A	5.04	4.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AGIO Agios Pharmaceuticals	N/A
CAPR Capricor Therapeutics	21.68%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
AGIO Agios Pharmaceuticals	5.40%
CAPR Capricor Therapeutics	9.20%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable

CAPR, ADMA, VCEL, and AGIO Headlines

Recent News About These Companies

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15 at 11:00 PM | seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

September 14 at 12:00 AM | seekingalpha.com

Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP

September 12, 2026 | marketbeat.com

Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

September 10, 2026 | marketbeat.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

September 8, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Vericel Corporation $VCEL

September 5, 2026 | marketbeat.com

115,630 Shares in Vericel Corporation $VCEL Bought by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Man Group plc Buys New Shares in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Formula Growth Ltd. Makes New $1.15 Million Investment in Vericel Corporation $VCEL

August 28, 2026 | marketbeat.com

Deutsche Bank AG Purchases Shares of 64,404 Vericel Corporation $VCEL

August 27, 2026 | marketbeat.com

EFG International AG Purchases Shares of 127,642 Vericel Corporation $VCEL

August 26, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 8,092,226 Vericel Corporation $VCEL

August 26, 2026 | marketbeat.com

398,365 Shares in Vericel Corporation $VCEL Bought by Osterweis Capital Management Inc.

August 25, 2026 | marketbeat.com

William Blair Investment Management LLC Purchases New Shares in Vericel Corporation $VCEL

August 22, 2026 | marketbeat.com

Madison Asset Management LLC Acquires Shares of 50,116 Vericel Corporation $VCEL

August 21, 2026 | marketbeat.com

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Lisanti Capital Growth LLC Acquires New Holdings in Vericel Corporation $VCEL

August 20, 2026 | marketbeat.com

Summit Creek Advisors LLC Purchases Shares of 219,312 Vericel Corporation $VCEL

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CAPR, ADMA, VCEL, and AGIO Company Descriptions

ADMA Biologics NASDAQ:ADMA

$8.95 +0.05 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$9.06 +0.11 (+1.23%)

As of 07:30 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Agios Pharmaceuticals NASDAQ:AGIO

$33.61 +0.66 (+2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$33.61 0.00 (0.00%)

As of 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$9.42 +0.86 (+10.05%)

Closing price 04:00 PM Eastern

Extended Trading

$9.44 +0.02 (+0.16%)

As of 07:56 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Vericel NASDAQ:VCEL

$40.03 -0.18 (-0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$40.06 +0.03 (+0.07%)

As of 07:30 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ADMA, VCEL, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ADMA, VCEL, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ADMA, VCEL, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAPR, ADMA, VCEL, and AGIO Company Descriptions

ADMA Biologics NASDAQ:ADMA

Agios Pharmaceuticals NASDAQ:AGIO

Capricor Therapeutics NASDAQ:CAPR

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ADMA, VCEL, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ADMA, VCEL, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ADMA, VCEL, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAPR, ADMA, VCEL, and AGIO Company Descriptions

ADMA Biologics NASDAQ:ADMA

Agios Pharmaceuticals NASDAQ:AGIO

Capricor Therapeutics NASDAQ:CAPR

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools